INTRODUCTION
============

Bronchial asthma is one of the most prevalent chronic diseases worldwide and is responsible for 1% of the entire annual global burden of disease ([@B1]). Although, there is no cure for asthma, pharmacotherapy can relief acute symptoms of the disease or reduce the underlying inflammatory processes in order to achieve effective asthma control. At present inhaled corticosteroids are the most commonly used anti-inflammatory drugs in asthma control and according to national and international guidelines, they are recommended as the first-line agents for persistent asthma, either alone or combined with long-acting beta-agonists ([@B2], [@B3]). Ciclesonide is a glucocorticosteroid-ester pro-drug, presently approved for persistent asthma control in many countries worldwide. It is produced in the form of a solution for inhalation by means of a pressurized metered-dose inhaler (MDI) with hydrofluoroalkane (HFA) 134a as a propellant. Efficacy of ciclesonide has been shown in some placebo-controlled comparative trials in children and adults ([@B4], [@B5]). In Europe, the preferred starting dose of ciclesonide in adults is 160 μg once daily. A lower dose of ciclesonide, 80 μg once daily, considerably improved lung function markers in comparison with placebo in patients with mild to moderate persistent asthma in two 12-week trials ([@B6], [@B7]). In addition, ciclesonide 80 μg once daily attenuated the early and late asthmatic reactions after allergen challenge and notably reduced exercise-induced bronchoconstriction after one week of therapy ([@B8], [@B9]). A comparative 12-week study in patients with persistent asthma (older than 12 years) demonstrated similar asthma control efficacy of two doses of ciclesonide, 80 μg and 160 μg once daily, and fluticasone propionate 100 μg twice daily ([@B10]).

The aim of the present study was to confirm the long-term efficacy of ciclesonide 80 μg once daily during 18 weeks in patients with mild persistent asthma. For this reason, ciclesonide was compared with fluticasone propionate 100 μg twice daily.

MATERIALS AND METHODS
=====================

Patients
--------

Female and male patients older than 12 years with a history of persistent bronchial asthma ([@B11]) for at least 6 months were enrolled. Patients were eligible to enter into a 2-week run-in period before randomization (baseline) if they had received inhaled corticosteroids (fluticasone propionate 250 μg/day or equivalent) at a constant dose during the last 4 weeks before the run-in period and if they showed FEV~1~ between 80% and 105% of predicted. The exclusion criteria were: other relevant lung disorders like chronic obstructive pulmonary disease, a severe concomitant pathology, a situation that prohibited the use of inhaled corticosteroids, or clinically related abnormal laboratory markers. Pregnant or breastfeeding female patients were excluded from the survey. Current smokers and ex-smokers with more than 10 packs/year, patients under immunotherapy, and patients with known history of allergy to inhaled corticosteroids were also excluded. The patients should not use systemic glucocorticosteroids during the past 4 weeks or more than twice during the past 6 months before the run-in period. For enrolling into the treatment period at baseline, patients had to have FEV~1~ between 61% and 90% of predicted, and a decrease in FEV~1~ of more than 10% compared to the onset of the run-in period.

Study design
------------

This was a national, double center, randomized, double blind study with a 2--4 week run-in period and an 18-week double-blind treatment phase. During the run-in phase, patients were prescribed only the rescue drug (inhaled salbutamol, 100 μg/puff) if needed. Patients who met the criteria for entering into the treatment phase were randomly divided in a 1:1 ratio to receive ciclesonide 80 μg once daily in the evening or fluticasone propionate 100 μg twice daily in the morning and evening (200 μg/day). No other anti-asthma agents, except for the rescue medication, were allowed during the treatment period. Randomization was performed by means of a computer-generated list (Program RANDOM). The patient information, study protocol, and consent form were approved by the Ethics Committee of the Iranian Ministry of Health and Medical Education and the study was registered in the Iranian registry of clinical trials: <http://www.irct.ir>. All patients gave written informed consent before inclusion in the study.

Efficacy assessments
--------------------

FEV~1~ and forced vital capacity (FVC) were measured at the time of randomization (baseline) and after 2, 4, 8, and 18 weeks of therapy. Spirometry was carried out in accordance with the standards set by the American Thoracic Society. At each centre, the same spirometry equipment was used during the whole trial period and the same person measured the variables. Spirometry was performed after 15--30 minutes, about 12 hours after the last use of study drugs and at least 4 hours after the last use of the rescue medication. For daily assessment of asthma control, patients had to record their asthma symptoms (daytime and nighttime) and the need for rescue medication (salbutamol). Asthma-specific quality of life was evaluated by means of self administered, standardized version of the Asthma Quality of Life Questionnaire (AQLQ \[S\]), ([@B11], [@B12]) which includes 32 questions in 4 domains: symptoms, activity limitations, exposure to environmental stimuli, and emotional function. Patients completed the questionnaire at baseline and at 8 and 18 weeks (or termination of the study) and answered to each question using a 7-point scale from 1 (maximal destruction) to 7 (no destruction). The net benefit in quality of life was measured as the proportion of patients with an increase of at least 0.5 in the total AQLQ (S) score (improvement) minus the proportion of patients with a decrease of at least 0.5 in total AQLQ (S) score (deterioration).

Tolerability and safety assessments
-----------------------------------

Adverse events (AEs) were recorded at every trial visit. The researcher defined the severity of AE as mild, moderate, or severe and evaluated the causal association between the AE and use of study drug. The patients' oropharynx was examined at each visit and a swab test was carried out if oral candidiasis was suspected. Vital sign items (blood pressure, heart rate) and physical examinations were conducted at the start of the run-in period and after 18 weeks of treatment (or at the time of premature discontinuation).

Statistical analysis
--------------------

Efficacy variables were analyzed according to an intention-to treat (ITT) and a per-protocol (PP) basis. Patients who had shown a baseline value of efficacy and who had received at least one dose of ciclesonide or fluticasone propionate were enrolled in the ITT analysis. The PP analysis was based on patients in the ITT population without major protocol violations. The safety analysis included all randomized patients who had received at least one dose of study medication (ITT population). The primary efficacy variable was the alteration in FEV~1~ \[L\] from baseline to the end of the treatment phase (18 weeks or the last \[applicable\] recorded measurement). Secondary efficacy variables consisted of changes in FVC from baseline to all scheduled visits, the percentage of patients with asthma exacerbations, the difference in the average percentage of days with asthma control in the last 14 days prior to baseline and the last 28 days of treatment, and the change from baseline to the end of the treatment period in the AQLQ (S) overall score. Variables assessed for tolerability and safety consisted of the number of patients with AEs, vital signs, physical examination, and the laboratory tests. The primary hypothesis of this survey was the non-inferiority of ciclesonide 80 μg once daily to fluticasone propionate 100 μg twice daily with reference to the primary variable. Non inferiority was also examined for the secondary variables FVC, and AQLQ (S) scores. The non-inferiority acceptance limits were set to −0.20 L for FEV~1~ and FVC, and −0.5 for the AQLQ (S) scores. The PP analysis was the primary analysis for verifying non-inferiority testing. The ITT analysis was performed to confirm the robustness of the results. A sample size of 230 patients (i.e., 115 patients in each treatment group) in the PP analysis was sufficient to ensure a power of 90% for correctly concluding non-inferiority regarding the primary variable under the following assumptions: one-sided level of significance of 2.5%, a mean difference in FEV~1~ for ciclesonide versus fluticasone propionate of −0.05 L with a standard deviation of 0.45 L, and a non-inferiority acceptance limit of −0.20 L. Primary and secondary lung function markers and AQLQ (S) scores were assessed by analysis of covariance, including baseline value and age as covariates and treatment, sex, and centre pool as factors. Non-inferiority was fulfilled if the entire 95% confidence interval (CI) of the difference between ciclesonide and fluticasone propionate (least square \[LS\] means) was above the predefined non-inferiority acceptance limit. Asthma symptom score sum and percentage of days with asthma control were tested non-parametrically (level of significance: 5%). The Wilcoxon signed-rank test modified according to Pratt was applied for within-treatment comparisons, and the Mann Whitney U-test was used for between treatment comparisons. Adverse events and other tolerability and safety variables were tested descriptively.

RESULTS
=======

Study population
----------------

Of the 300 patients who enrolled in the run-in phase, 230 were assigned to one of the two treatment groups (ITT: ciclesonide 80 μg once daily, n =115; fluticasone propionate 100 μg twice daily, n =115). In total, 215 patients completed the study, 110 patients in the ciclesonide group and 105 patients in the fluticasone propionate groups ([Figure 1](#F1){ref-type="fig"}). The main reason for premature trial discontinuation was patient's request or unwillingness to continue. All randomized patients received as a minimum one dose of study drug and were enrolled in the ITT and safety measurements. Except for smoking status (relatively more never-smokers were found in the ciclesonide group than in the fluticasone propionate group), the baseline characteristics were similar in both treatment groups ([Table 1](#T1){ref-type="table"}). Most patients had mild or moderate persistent asthma (ITT: ciclesonide, 92%; fluticasone propionate, 89%) based on the Global Initiative for Asthma (GINA) 2006 classification. According to the diary entries, the median acquiescence to study drug was 99% (range 99--100%) in the two treatment groups.
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###### 

Demographic data and baseline characteristics

  **Variables**                                           **ITT (n=230)**   **PP (n=215)**                   
  ------------------------------------------------------- ----------------- ---------------- --------------- ---------------
                                                          CIC80 (n=115)     FP200 (n=115)    CIC80 (n=110)   FP200 (n=105)
  **Age (year), Median (range)**                          38 (15--65)       41 (15--65)      37 (15--65)     40 (15--65)
  **Weight (Kg), mean± SD**                               73±16.2           72±15.0          74±17.5         73±17.1
  **Height (cm). Mean± SD**                               167±7.2           167±9.5          166±8.3         167±9.1
  **Sex, n (%)**                                                                                             
    Male                                                  60 (52)           59 (51)          54 (42)         44 (36)
    Female                                                55 (48)           56 (49)          75 (58)         78 (64)
  **Smoking status, n (%)**                                                                                  
    Never-smoker                                          89 (78)           79 (69)          84 (77)         73 (70)
    Ex-/current smoker[^1^](#TFN2){ref-type="table-fn"}   26 (22)           36 (31)          26 (23)         32 (30)
  **Asthma duration (months), median (range)**            121 (7--577)      124 (7--700)     117 (7--577)    12 (7--700)
  **FEV~1~ (L), Mean± SD**                                2.34±0.7          2.36±0.5         2.36±0.6        2.37±0.6
  **FEV~1~ (% predicted), Mean± SD**                      73.5±6.6          75.0±6.1         75.2±6.7        75.7±6.2
  **Reversibility, FEV~1~ (% increase)**                  16.3±7.1          16.7±7.2         16.5±7.2        16.6±7.3

CIC80= ciclesonide 80μg once daily; FEV~1~= Forced expiratory volume in 1s; FP200= Fluticasone propionate 100μg twice daily; ICS= Inhaled corticosteroid; ITT= Intention-to-treat; PP=Per-protocol; SD= Standard deviation.

Ex-smoker: Smoking cessation at least one year ago

Lung function
-------------

Both agents, fluticasone propionate 100 μg twice daily and ciclesonide 80 μg once daily, improved FEV~1~ \[L\] similarly during the 18-week treatment period. Progressions were statistically significant in comparison with baseline measurements (P\< 0.0001, groups at all time points, PP and ITT analyses). After a quick FEV~1~ improvement during the first 2 weeks of treatment, a plateau phase was detected about 8 weeks after treatment, which remained approximately steady until the end of the treatment phase at 18 weeks. At the end of treatment period, the LS mean change from baseline in FEV~1~ was 0.45 L in the ciclesonide group and 0.51 L in the fluticasone propionate group (PP analysis); similar results were found in the ITT analysis ([Table 2](#T2){ref-type="table"}). Non-inferiority of ciclesonide 80 μg once daily to fluticasone propionate 100 μg twice daily was displayed for change in FEV~1~ from baseline to the end of the treatment phase (PP and ITT analyses; [Table 2](#T2){ref-type="table"}). FVC as the secondary lung function variable significantly improved from baseline in the fluticasone propionate group and in the ciclesonide group (P \< 0.0001, both groups, all post-baseline visits, PP and ITT analyses; [Table 2](#T2){ref-type="table"}). Non-inferiority of ciclesonide 80 μg once daily to fluticasone propionate 100 μg twice daily was confirmed for the changes in FVC from baseline to the end of the treatment period in both the PP and ITT analyses ([Table 2](#T2){ref-type="table"}).

###### 

Lung function measures and AQLQ score after 18 weeks of treatment with ciclesonide or fluticasone propionate

  **Variables**                                                                      ITT (n=230)     PP (n=215)                      
  ---------------------------------------------------------------------------------- --------------- --------------- --------------- ---------------
                                                                                     CIC80 (n=115)   FP200 (n=115)   CIC80 (n=110)   FP200 (n=105)
  **Change from baseline[^1^](#TFN4){ref-type="table-fn"} FEV~1~ (L), Spirometry**                                                   
  Baseline, LS mean                                                                  2.38            2.38            2.36            2.36
  Change, LS mean± SD                                                                0.45±0.03       0.51±0.03       0.45±0.03       0.51±0.03
  P-value (2-sided)                                                                  \<0.0001        \<0.0001        \<0.0001        \<0.0001
  **FVC (L), Spirometry**                                                                                                            
  Baseline, LS mean                                                                  3.24            3.24            3.21            3.21
  Change, LS mean± SD                                                                0.5±0.03        0.56±0.03       0.56±0.04       0.59±0.04
  P-value (2-sided)                                                                  \<0.0001        \<0.0001        \<0.0001        \<0.0001
  **Morning PEF (L/min), diary**                                                                                                     
  Baseline, LS mean                                                                  362.9           362.9           363.5           363.5
  Change, LS mean± SD                                                                23.0±3.4        34.5±3.5        22.9±3.8        32.9±3.8
  P-value (2-sided)                                                                  \<0.0001        \<0.0001        \<0.0001        \<0.0001
  **Change from baseline in AQLQ (S) scores**                                        0.40±0.05       0.45±0.05       0.40±0.06       0.42±0.06
  P-value (2-sided)                                                                  \<0.0001        \<0.0001        \<0.0001        \<0.0001

CIC80= Ciclesonide 80μg once daily; FEV~1~= Forced expiratory volume in 1s; FP200= Fluticasone propionate 100μg twice daily; FVC=Forced vital capacity; ITT= Intention-to-treat; LS= Least square; PEF= Peak expiratory flow; PP=per-Protocol; SE= Standard error

Change from baseline to 18 weeks

Quality of life
---------------

Asthma-specific quality of life improved considerably from baseline in two treatment groups with regard to AQLQ (S) overall score ([Table 2](#T2){ref-type="table"}). Non-inferiority of ciclesonide 80 μg once daily to fluticasone propionate 100 μg twice daily was demonstrated for the change from baseline to the end of the treatment phase in the AQLQ (S) overall score and all individual domain scores (P \< 0.0001, one-sided, all scores, PP and ITT analyses).

Tolerability and safety
-----------------------

The incidence of treatment-emergent adverse events was similar in both groups: 14% (n=30) of patients treated with ciclesonide 80 μg once daily and 18% (n = 38) of patients treated with fluticasone propionate 100 μg twice daily had at least one adverse event. Nasopharyngitis and upper respiratory tract infection were the most common adverse events in the two treatment groups. No deaths occurred over the trial period. At the end of the treatment phase, no clinically significant changes in physical examination and laboratory markers were seen in any of the groups. The mean blood pressure and the mean heart rate were stable during the study period in the two treatment groups.

DISCUSSION
==========

The current survey evaluated the efficacy of low-dose ciclesonide (80 μg/day, prescribed once daily in the evening) in comparison with fluticasone propionate (200 μg/day, 100 μg prescribed twice daily) in patients with mild to moderate persistent asthma. Our findings showed that both agents improved lung function and led to asthma control during a prolonged treatment period of 18 weeks. These results are similar to the findings of a previous double-blind trial in patients with persistent asthma, which demonstrated similar efficacy of ciclesonide 80 μg once daily and fluticasone propionate 100 μg twice daily over a shorter treatment period of 12 weeks ([@B10]). The clinical efficiency of both fluticasone propionate 100 μg twice daily and ciclesonide 80 μg once daily has been shown in placebo-controlled trials ([@B6], [@B7], [@B13]). A randomized, double-blind survey in patients older than 12 years with mild to moderate persistent asthma showed that ciclesonide 160 μg once daily and fluticasone propionate 100 μg twice daily were similar in both improving lung function and reducing asthma symptoms and rescue drug use ([@B14]). HFA based, fine particle formulations like ciclesonide are largely deposited in the peripheral regions of the lung ([@B15], [@B16]). They seem to be more effective in controlling eosinophilic inflammation in the small airways than more conventional formulations with larger particle sizes ([@B17]--[@B19]). Optimal delivery to all parts of the lung may have special importance when using reduced corticosteroid doses. To prevent the incidence of unwilling side effects in association with long-term corticosteroid treatment, modern guidelines recommend prescribing the inhaled corticosteroids with the lowest effective dose ([@B2], [@B20]--[@B23]). It is necessary to sufficiently investigate and document the efficacy of low-dose inhaled corticosteroids, particularly in long-term treatments. A recent survey on mild asthma demonstrated beneficial effects of prolonged regular treatment with a minimal dose of fluticasone propionate 100 μg/day to preserve the progressions achieved via higher dose of 250 μg/day ([@B24]). Ciclesonide resulted in good asthma control in most asthma patients at a dose of 160 μg once daily ([@B7], [@B10], [@B14], [@B25]--[@B27]). However, efficacy information for low-dose ciclesonide was provided by trials with treatment periods not more than 12 weeks ([@B6], [@B7], [@B28]). The current survey confirmed that low-dose ciclesonide was an effective anti-inflammatory controller medication and showed its efficacy in mild to moderate asthma during a long-term treatment period of 18 weeks. Recent international asthma therapy guidelines suggest low-dose inhaled corticosteroids as initial controller treatment in persistent asthma. In a stepwise management approach, long-acting beta-agonists can be added to the inhaled corticosteroids for patients in whom adequate asthma control cannot be achieved with inhaled corticosteroids alone ([@B2], [@B3]). On the other hand, adding a long-acting beta-agonist to inhaled corticosteroids can provide no additional improvement in these patients and may result in unnecessary costs ([@B29], [@B30]). Monotherapy with an inhaled corticosteroid often leads to sufficient control in the majority of patients with persistent asthma ([@B2]). In this 18-week survey, both inhaled corticosteroid monotherapy treatments demonstrated good asthma control in patients with mild to moderate persistent asthma. To confirm the need for inhaled corticosteroid therapy, patients had to display worsening in lung function following the baseline phase after discontinuation of their inhaled corticosteroid. As the patients demonstrated satisfactory response to the low-dose ciclesonide, there is a possibility that some of the patients known as having moderate asthma actually had mild asthma. In the general population, patients with mild persistent asthma account for a large proportion of all asthmatic patients (up to 70%) ([@B31]). Both ciclesonide 80 μg once daily and fluticasone propionate 100 μg twice daily significantly improved asthma-specific quality of life as examined by the standardized AQLQ. Non-inferiority of ciclesonide to fluticasone propionate with regard to the improvements in the AQLQ (S) overall score after 18 weeks of treatment was shown. The baseline AQLQ (S) scores were comparatively high in both groups. However, both treatments caused statistically significant improvements in the AQLQ (S) overall score. The incidence of adverse events during the 18-week trial period was low and similar in both groups. Relatively higher number of associated adverse events, which were mainly local reactions such as oral candidiasis, was detected in fluticasone propionate group than in the ciclesonide group. This is not unexpected, because the daily dose of fluticasone propionate was twice as high as that of ciclesonide. Nevertheless, the incidence of local oropharyngeal adverse events reported in previous trials evaluating comparable doses of the two inhaled corticosteroids also designated better local tolerability of ciclesonide ([@B32], [@B33]). Inhaled corticosteroids commonly result in minimal side effects at low to moderate doses. On the other hand, non-compliance is a trouble in long-term asthma management and patients who experience adverse effects are more likely to discontinue their drugs than patients who do not ([@B34]).

CONCLUSION
==========

This 18-week study confirmed similar efficacy of fluticasone propionate 100 μg twice daily and ciclesonide 80 μg once daily in patients with mild to moderate persistent asthma and showed that low-dose ciclesonide was efficient for long-term treatments. According to these findings, it can be concluded that ciclesonide at a dose of 80 μg once daily can provide efficient maintenance therapy for mild to moderate persistent asthma.
